一名晚期非小细胞肺癌患者因表皮生长因子受体-TKI 诱导的因子 V 缺乏症：首例病例报告

IF 4.5 2区医学 Q1 ONCOLOGY Lung Cancer Pub Date : 2024-07-01 DOI:10.1016/j.lungcan.2024.107869

Chinatsu Yoshizaki , Yuki Yoshida , Shiho Nohmi , Yoshihiro Go , Rui Kusakado , Saori Kawamura , Daisuke Inoue , Nobuyuki Kabasawa , Fumihiro Yamaguchi

{"title":"一名晚期非小细胞肺癌患者因表皮生长因子受体-TKI 诱导的因子 V 缺乏症：首例病例报告","authors":"Chinatsu Yoshizaki , Yuki Yoshida , Shiho Nohmi , Yoshihiro Go , Rui Kusakado , Saori Kawamura , Daisuke Inoue , Nobuyuki Kabasawa , Fumihiro Yamaguchi","doi":"10.1016/j.lungcan.2024.107869","DOIUrl":null,"url":null,"abstract":"<div><p>Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is routinely prescribed as first-line therapy for advanced non-small cell lung cancer, regardless of the presence of the T790M resistance mutation. This study reports a rare case of Factor V inhibitor detection during osimertinib therapy in a patient with lung adenocarcinoma. These findings underscore the importance of vigilant monitoring for coagulation abnormalities during EGFR-TKI therapy.</p></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"194 ","pages":"Article 107869"},"PeriodicalIF":4.5000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"EGFR-TKI-induced Factor V deficiency in a patient with advanced non-small cell lung cancer: The first case report\",\"authors\":\"Chinatsu Yoshizaki , Yuki Yoshida , Shiho Nohmi , Yoshihiro Go , Rui Kusakado , Saori Kawamura , Daisuke Inoue , Nobuyuki Kabasawa , Fumihiro Yamaguchi\",\"doi\":\"10.1016/j.lungcan.2024.107869\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is routinely prescribed as first-line therapy for advanced non-small cell lung cancer, regardless of the presence of the T790M resistance mutation. This study reports a rare case of Factor V inhibitor detection during osimertinib therapy in a patient with lung adenocarcinoma. These findings underscore the importance of vigilant monitoring for coagulation abnormalities during EGFR-TKI therapy.</p></div>\",\"PeriodicalId\":18129,\"journal\":{\"name\":\"Lung Cancer\",\"volume\":\"194 \",\"pages\":\"Article 107869\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lung Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0169500224004033\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0169500224004033","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

奥希替尼是第三代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI），是晚期非小细胞肺癌一线治疗的常规处方药，无论是否存在T790M耐药突变。本研究报告了一例罕见的肺腺癌患者在奥希替尼治疗期间检测到因子V抑制剂的病例。这些发现强调了在 EGFR-TKI 治疗期间警惕监测凝血异常的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

EGFR-TKI-induced Factor V deficiency in a patient with advanced non-small cell lung cancer: The first case report

Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is routinely prescribed as first-line therapy for advanced non-small cell lung cancer, regardless of the presence of the T790M resistance mutation. This study reports a rare case of Factor V inhibitor detection during osimertinib therapy in a patient with lung adenocarcinoma. These findings underscore the importance of vigilant monitoring for coagulation abnormalities during EGFR-TKI therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Lung Cancer 医学-呼吸系统

CiteScore

9.40

自引率

3.80%

发文量

407

审稿时长

25 days

期刊介绍： Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.